Kronos Bio (KRON) News Today $0.99 -0.02 (-1.92%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Up 16.5% in DecemberKronos Bio, Inc. (NASDAQ:KRON - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 577,700 shares, a growth of 16.5% from the December 15th total of 496,000 shares. Approximately 1.5% of the company's stock are sold short. Based on an average trading volume of 255,900 shares, the short-interest ratio is presently 2.3 days.January 19 at 6:37 AM | marketbeat.comWe Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth CarefullyJanuary 13, 2025 | uk.finance.yahoo.comKronos Bio (NASDAQ:KRON) Stock Price Down 1.8% - Here's What HappenedKronos Bio (NASDAQ:KRON) Trading Down 1.8% - What's Next?January 1, 2025 | marketbeat.comKronos Bio Ends Collaboration with Genentech and RocheDecember 27, 2024 | tipranks.comKronos Bio Inc Ordinary SharesDecember 13, 2024 | morningstar.comKronos Bio (NASDAQ:KRON) Shares Up 8.5% - Still a Buy?Kronos Bio (NASDAQ:KRON) Stock Price Up 8.5% - Still a Buy?December 6, 2024 | marketbeat.comStruggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staffDecember 4, 2024 | msn.comKronos Bio announces workforce reduction of 83% by year-endNovember 28, 2024 | markets.businessinsider.comKronos Bio to lay off 83% of staff as CEO steps downNovember 28, 2024 | bizjournals.comBiotech with Cambridge lab slashes 83% of staff, CEO departsNovember 28, 2024 | bizjournals.comKronos Bio CEO Norbert Bischofberger steps down, Deborah Knobelman named interimNovember 28, 2024 | markets.businessinsider.comKronos Bio announces interim CEO; over 80% of staff reductionNovember 28, 2024 | msn.comKronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-UpNovember 28, 2024 | msn.comKronos Bio Announces CEO Transition and Reduction in ForceNovember 27, 2024 | globenewswire.comPetri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firmNovember 22, 2024 | bizjournals.comKronos Bio Third Quarter 2024 Earnings: Beats ExpectationsNovember 16, 2024 | finance.yahoo.comKronos Bio to present preclinical data from p300 KAT inhibitor programNovember 16, 2024 | markets.businessinsider.comKronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNovember 15, 2024 | uk.finance.yahoo.comKronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024November 14, 2024 | globenewswire.comTD Cowen downgrades Kronos Bio (KRON) to a HoldNovember 14, 2024 | markets.businessinsider.comKronos Bio downgraded to Hold from Buy at TD CowenNovember 14, 2024 | markets.businessinsider.comKronos mulls ‘strategic alternatives’ after axing cancer drug developmentNovember 14, 2024 | yahoo.comKronos Bio (NASDAQ:KRON) Rating Lowered to "Neutral" at Piper SandlerPiper Sandler lowered shares of Kronos Bio from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $6.00 to $1.00 in a report on Thursday.November 14, 2024 | marketbeat.comKronos Bio (NASDAQ:KRON) Stock Rating Lowered by TD CowenTD Cowen downgraded Kronos Bio from a "buy" rating to a "hold" rating in a report on Thursday.November 14, 2024 | marketbeat.comKronos Bio files $250M mixed securities shelfNovember 8, 2024 | markets.businessinsider.comKronos Bio to present data at ASH annual meeting on p300 KAT inhibitor programNovember 5, 2024 | markets.businessinsider.comKronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNovember 5, 2024 | finance.yahoo.comKronos Bio announces preclinical data from p300 KAT inhibitor programOctober 24, 2024 | markets.businessinsider.comKronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsOctober 23, 2024 | globenewswire.comPiper Sandler Remains a Buy on Kronos Bio (KRON)October 9, 2024 | markets.businessinsider.comKronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsOctober 9, 2024 | globenewswire.comKronos Bio (NASDAQ:KRON) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comKronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseOctober 8, 2024 | markets.businessinsider.comKronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's DiseaseOctober 7, 2024 | globenewswire.comA reaction following a fire at a Georgia chemical plant is forcing evacuations and road closuresSeptember 30, 2024 | msn.comKronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapySeptember 25, 2024 | globenewswire.comKronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerSeptember 23, 2024 | globenewswire.comKronos Bio Announces Participation in Medical and Investor Conferences in SeptemberSeptember 3, 2024 | globenewswire.comIOVA Aug 2024 8.500 put (IOVA240830P00008500)August 24, 2024 | finance.yahoo.comQ3 2024 EPS Estimates for Kronos Bio, Inc. (NASDAQ:KRON) Raised by AnalystKronos Bio, Inc. (NASDAQ:KRON - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2024 earnings estimates for shares of Kronos Bio in a research note issued on Monday, August 19th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.29) per share for the quAugust 21, 2024 | marketbeat.comKronos Bio (NASDAQ:KRON) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $2.25 price objective on shares of Kronos Bio in a research report on Monday.August 19, 2024 | marketbeat.comKronos Bio Second Quarter 2024 Earnings: Beats ExpectationsAugust 12, 2024 | finance.yahoo.comBuy Rating Affirmed for Kronos Bio Amid Promising Clinical Developments and Strategic ExpansionAugust 9, 2024 | markets.businessinsider.comKronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateAugust 9, 2024 | markets.businessinsider.comFY2025 Earnings Forecast for Kronos Bio, Inc. Issued By HC Wainwright (NASDAQ:KRON)Kronos Bio, Inc. (NASDAQ:KRON - Free Report) - Equities researchers at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Kronos Bio in a research report issued to clients and investors on Wednesday, July 31st. HC Wainwright analyst R. Burns forecasts that the company will pAugust 2, 2024 | marketbeat.comKronos Bio's (KRON) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $2.25 target price on shares of Kronos Bio in a report on Thursday.August 1, 2024 | marketbeat.comBuy Rating on Kronos Bio Backed by Potential of KB-0742 and Solid Valuation ModelJuly 31, 2024 | markets.businessinsider.comKronos Bio Inc (KRON)July 26, 2024 | investing.comKronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerJuly 23, 2024 | globenewswire.comKronos Bio, Inc. (NASDAQ:KRON) CEO Acquires $480,692.16 in StockJuly 2, 2024 | insidertrades.com Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Media Mentions By Week KRON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KRON News Sentiment▼0.570.46▲Average Medical News Sentiment KRON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KRON Articles This Week▼11▲KRON Articles Average Week Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CMPS News Today CGC News Today AMRN News Today GOSS News Today CADL News Today MOLN News Today FULC News Today LRMR News Today FDMT News Today ACB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KRON) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KRON Stock Alerts